Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C, Liang X, Jiang G, Liu Z, Li X, Zuo L, Luo L, Wang J, Zhao MH, Liu Z, Cai GY, Hao L, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP. Chen N, et al. N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340116 Clinical Trial.
Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of anemia in patients undergoing dialysis. ...CONCLUSIONS: Oral roxadustat wa …
Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alf …
Long-term efficacy, safety, and medication compliance of roxadustat on peritoneal dialysis patients with renal anemia affected by the COVID-19 pandemic: a retrospective study.
Bao L, Bian X, Zhang A, Huang J, Ren L, Luo C. Bao L, et al. Ann Palliat Med. 2022 Jun;11(6):2017-2024. doi: 10.21037/apm-22-555. Ann Palliat Med. 2022. PMID: 35817736 Free article.
BACKGROUND: Current studies have limited data on long-term treatment safety and medication compliance of roxadustat for renal anemia in peritoneal dialysis (PD) patients. We aimed to analyze the long-term effic …
BACKGROUND: Current studies have limited data on long-term treatment safety and medication compliance of roxadustat
Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L, Locatelli F. Del Vecchio L, et al. Expert Opin Investig Drugs. 2018 Jan;27(1):125-133. doi: 10.1080/13543784.2018.1417386. Epub 2017 Dec 25. Expert Opin Investig Drugs. 2018. PMID: 29254377
Currently its management is based on iron and erythropoiesis-stimulating agents (ESAs) therapy. Given safety issues on ESA therapy and excessive iron use, anaemia management is still suboptimal. ...Expert opinion: Phase-II clinical trials have shown that r
Currently its management is based on iron and erythropoiesis-stimulating agents (ESAs) therapy. Given safety issues on ESA therapy
Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study.
Zhao B, Yang X, Li W, Zhu H, Meng Q, Ma Y, Liu Y, Zhou Y, Lin J, Zhai C, Zhao L, Sun J, Wang R. Zhao B, et al. Clin Kidney J. 2023 Apr 10;16(9):1500-1507. doi: 10.1093/ckj/sfad080. eCollection 2023 Sep. Clin Kidney J. 2023. PMID: 37664567 Free PMC article.
BACKGROUND: Reduced survival of red blood cells (RBCs) in patients with chronic kidney disease (CKD) is thought to contribute to renal anaemia. ...METHODS: In this single-centre, single-arm trial, patients who had been undergoing haemodialysis a …
BACKGROUND: Reduced survival of red blood cells (RBCs) in patients with chronic kidney disease (CKD) is thought to contribute to r